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Peri-operative tissue injury triggers the development of Transplant Coronary Artery Disease (TCAD). Animal studies have shown that
induction of heme oxygenase (HO)-1 protects the donor organ from the development of TCAD. To investigate the role of HO-1 in TCAD
after clinical heart transplantation, we measured intragraft mRNA expression of HO-1, HIF-1a, TGF-h, FLIP, and the Bcl-2/Bax balance.
Immunohistochemical staining of HO-1 was performed to determine its origin. Myocardial biopsies taken at the end of the transplantation
procedure (time 0), at 1 week and at 10 months after transplantation were studied from recipients with or without angiographic signs of
accelerated TCAD, diagnosed after 1 year. At time 0, no differences in mRNA expression for any of the measured parameters were found
between TCAD positive and negative patients. At 1 week, mRNA expression of HO-1 and TGF-h was higher in grafts that developed
accelerated TCAD ( p=0.001 and p=0.0002). These higher mRNA levels were accompanied by a pro-apoptotic shift in Bcl-2/Bax ( p=0.02),
suggesting proneness for apoptosis via the mitochondrial pathway. Immunohistochemical staining showed that HO-1 was mainly produced
by infiltrating macrophages. At 10 months, again HO-1 and TGF-h levels were high in TCAD positive patients ( p=0.02 and p=0.05), but the
expression of apoptotic markers was comparable at this time point. Our results suggest that a higher HO-1 by macrophages in our patient
population might be an adaptive response to tissue injury and inflammation, reflecting damage due to the transplantation procedure that
finally results in TCAD.
D 2004 Elsevier B.V. All rights reserved.
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Transplant coronary artery disease (TCAD) is the cause
of morbidity and mortality in a considerable number of heart
transplant recipients [1]. TCAD is a chronic inflammatory
process characterized by progressive and diffuse intimal
thickening, due to migration of macrophages, migration and
proliferation of T-cells and smooth muscle cells, collagen0966-3274/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.trim.2004.08.002
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E-mail address: cholweg@cvmed.stanford.edu (C.T.J. Holweg).accumulation and fibrosis [2]. Oxidative stress due to peri-
operative ischemia followed by reperfusion might be an
early trigger for TCAD [2,3]. Oxidative stress leads to
apoptosis and necrosis of endothelial cells, vascular smooth
muscle cells and cardiac myocytes. This could subsequently
result in activation of cytokines and growth factors, like
IFN-g, PDGF-a, bFGF and TGF-h, that are involved in
processes causing intimal thickening of the coronary arteries
of human cardiac allografts [4,5].
The anti-oxidant enzyme Heme Oxygenase (HO)-1
catalyzes the degradation of heme into biliverdin, iron3 (2004) 265–272
C.T.J. Holweg et al. / Transplant Immunology 13 (2004) 265–272266and carbon monoxide (CO). Biliverdin is subsequently
converted into bilirubin. These catabolic end products are
thought to be responsible for the anti-inflammatory, anti-
oxidant, and anti-apoptotic properties of HO-1 [6]. Upre-
gulation of HO-1 might be a mechanism to protect cells
from damage due to ischemia, reperfusion and inflamma-
tion [6,7]. Consequently HO-1 might prevent the induction
of TCAD. Indeed, animal studies demonstrated that
induction of HO-1 with an adenovirus-HO-1 construct or
by cobalt protoporphyrin (CoPP) prior to or shortly after
transplantation protects against the development of TCAD
[8,9].2. Objective
To investigate whether HO-1 represents a factor by
which the donor organ is protected from the initiation and
progression of accelerated TCAD in human cardiac recip-
ients, we measured intragraft mRNA expression levels of
HO-1. In addition, we studied the mechanism by which
HO-1 acts and therefore, we determined mRNA expression
levels of Hypoxia Inducible Factor-(HIF)1a, a transcription
factor for HO-1; TGF-h, a growth factor known to be
involved in the development of TCAD [4,10] and a
regulator of HO-1 production [11]; FLIP (short and long),
an anti-apoptotic marker of the TNF-a-Fas/FasL induced
apoptosis route and Bax and Bcl-2, pro- and anti-apoptotic
markers of the mitochondrial apoptosis pathway. These
parameters were measured in myocardial biopsies (MB)
taken at the time of graft implantation (time 0), early after
transplantation (1 week) and to the end of the first year after
transplantation (10 months). Finally to establish the origin
of HO-1, we performed immunohistochemical staining of
HO-1 protein.3. Material and methods
3.1. Patients
Intragraft mRNA expression of HO-1, HIF-1a, TGF-h,
FLIPS+L, Bax, Bcl-2 and 18S RNA (housekeeping gene)
was studied in relation to accelerated TCAD. Therefore,
myocardial biopsies (MB) from heart transplant recipients
with and without early signs (at 1 year) of accelerated
TCAD were selected. Coronary angiography was routinely
performed at 1 year after transplantation for diagnosis of
early signs of TCAD, which were defined as all abnormal-
ities of the epicardial as well as the intramyocardial
branches, including minimal wall irregularities observed
by visual assessment of the coronary angiogram. Coronary
arteriograms had been assessed long before mRNA meas-
urements. An angiographic diagnosis was made by con-
sensus of two observers with experience in the evaluation of
post-transplant arteriograms [12]. Pre-transplant arterio-grams of the donors were not routinely performed and
therefore not available.
MB were taken from the left ventricle at the end of graft
implantation, before weaning from extra corporeal circu-
lation (time 0, without TCAD, n=12 and with TCAD,
n=11), and from the right side of the interventricular septum
early after transplantation (week 1, without TCAD, n=8 and
with TCAD, n=8) and during the development of TCAD
(10 months after transplantation, without TCAD, n=13 and
with TCAD, n=14). All biopsies were free of signs for acute
rejection (grade 0 or 1A, ISHLT criteria) [13]. Unfortu-
nately, the studied biopsies were not all from a consistent
cohort of patient. Biopsies of all three time-points were
available from seven patients and of two time-points from
10 patients. Patient demographics at the different time
points of mRNA measurements are summarized in Table 1.
All patients were on Cyclosporine A and low dose steroids
as maintenance immunosuppressive therapy. Cyclosporine
A was aimed to keep 12 h through levels between 250 and
350 ng/ml in the first 6 months after transplantation and
between 100 and 200 ng/ml after 6 months. Cytomegalo-
virus (CMV) infection was defined as any appearance of
immunoglobulin M or isolation of CMV from urine, throat
or blood or any demonstration of immediate early antigen.
CMV disease was diagnosed when infection co-existed with
two of the following symptoms: fever of more than 38 8C
for at least two consecutive days, gastrointestinal, lung,
retina or central nervous system involvement, leucopenia,
thrombocytopenia, elevation of serum alanine or aspartate
aminotransferases. CMV seronegative recipients received
seronegative blood products and were, when receiving a
heart of a seropositive donor, treated with anti-CMV
hyperimmunoglobulins for passive immunization. All heart
transplant recipients gave permission to use their material
and data for research purposes.
3.2. Total RNA extraction, cDNA synthesis and real-time
polymerase chain reaction
MB were snap-frozen in liquid nitrogen and stored at
80 8C until use. Total RNA isolation and cDNA synthesis
were performed as described previously [5]. The mRNA
levels of HO-1, HIF-1a, TGF-h, FLIP, Bcl-2 and Bax and
the RNA level of 18S were measured using real-time PCR
in the ABI PrismR 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) as described
in detail before [14]. For TGF-h and 18S, pre-developed
TaqManR assays (Applied Biosystems) and for Bax and
Bcl-2 primers and FRET probes (Biosource International,
Camarillo, CA, USA) were used. For HO-1, HIF-1a and
FLIP (detecting both FLIPS and FLIPL) we designed the
following primers and probes: HO-1 sense primer: 5V-TGC-
TCA-ACA-TCC-AGC-TCT-TTG-A-3V; HO-1 anti-sense
primer: 5V-GCA-GAA-TCT-TGC-ACT-TTG-TTG-CT-3V;
HO-1 probe: FAM-5V-AGT-TGC-AGG-AGC-TGC-TGA-
CCC-ATG-AC-3V; HIF-1a sense primer: 5V-AAC-ATG-
Table 1
Characteristics of patients at time points of intragraft mRNA expression measurement
Before transplantation Week 1 Month 10
TCAD
neg n=12
TCAD
pos n=11
p-value TCAD
neg n=8
TCAD
pos n=8
p-value TCAD
neg n=13
TCAD
pos n=14
p-value
Recipient age (years)a 54.0
(19.2–65.2)
57.3
(14.2–65.3)
0.83b 54.0
(19.2–61.9)
56.3
(41.9–61.3)
0.80b 52.2
(19.2–65.0)
55.2
(14.2–63.7)
0.56b
Donor age (years)a 31.5
(13.0–52.0)
38.0
(17.0–49.0)
0.21b 32.5
(13.0–43.0)
40.5
(31.0–49.0)
0.07b 34.0
(22.0–52.0)
36.0
(17.0–49.0)
0.96b
Recipient gender (M/F) 11/1 9/2 0.59c 7/1 7/1 1.0c 13/0 12/2 0.48c
Donor gender (M/F) 7/5 5/6 0.68c 7/1 4/4 0.28c 7/6 5/9 0.45c
Gender mismatch
(no/yes)
6/6 7/4 0.68c 6/2 5/3 1.0c 7/6 7/7 1.0c
Cause of braindeath
(donor) Cerebrovascular/
trauma/unknown
7/4/1 6/5/0 0.68c 4/3/1 5/3/0 1.0c 7/5/1 6/7/1 0.84c
Time of brain death of
donor (min)*
619
(387–920)
538
(167–810)
0.19b 598
(387–920)
529
(390–810)
0.78b 595
(390–920)
535
(217–810)
0.12b
Vasoactive drugs in donor
(no/yes/unknown)
2/9/1 0/11/0 0.34c 2/6/0 0/8/0 0.47c 1/11/1 0/12/2 1.0c
Heart disease (recipient)
CMP/IHD/other
4/7/1 2/8/1 0.80c 5/3/0 1/6/1 0.12z 4/8/1 4/8/1 1.0c
Cold ischemia time (min)a 171
(136–197)
190
(127–220)
0.37b 173
(140–197)
178
(140–279)
0.54b 171
(110–245)
178
(128–279)
0.46b
HLA AB mismatchesa 3.0
(2.0–4.0)
3.0
(2.0–4.0)
0.15b 3.0
(2.0–4.0)
4.0
(2.0–4.0)
0.50b 3.0
(2.0–4.0)
3.0
(1.0–4.0)
0.33b
HLA-DR mismatchesa 2.0
(0.0–2.0)
2.0
(0.0–2.0)
0.78b 2.0
(0.0–2.0)
2.0
(0.0–2.0)
0.72b 2.0
(0.0–2.0)
2.0
(0.0–2.0)
0.55b
Induction therapy
None/anti-T-cell/
anti-CD25
1/7/4 2/5/4 0.86c 0/5/3 1/5/2 1.0c 3/9/1 3/8/3 0.75c
Nr of AR first yeara 1.0
(0.0–4.0)
4.0
(0.0–5.0)
0.04b 1.0
(0.0–3.0)
1.5
(0.0–5.0)
0.57b 1.0
(0.0–3.0)
2.0
(0.0–5.0)
0.33b
CMV infection (no/yes) 9/3 5/6 0.21z 7/1 4/4 0.28c 8/5 8/6 1.0c
CMV disease (no/yes) 10/2 9/2 1.0c 8/0 6/2 0.47c 9/4 9/5 1.0c
Total cholesterol at 1-year
(nmol/L)a
7.0
(4.0–9.9)
6.5
(4.3–11.0)
0.73b 5.1
(4.0–9.1)
7.4 (4.7–11.0) 0.23b 6.4
(4.8–9.1)
6.4
(4.7–11.0)
0.98b
Triglycerides at 1-year
(nmol/L)a
2.1
(0.7–4.4)
2.9
(1.3–4.8)
0.48b 2.0
(0.7–2.4)
2.6 (0.9–3.2) 0.34b 2.8
(1.2–5.8)
2.1
(0.9–3.2)
0.10b
HMG-CoA-reductase
inhibitors (no/yes)
10/2 11/0 0.48c 6/2 8/0 0.47c 9/4 11/3 0.68c
TCAD was diagnosed at 1 year.
AR: acute rejection, CMP: dilated cardiomyopathy, IHD: ischemic heart disease. Time of brain death of the donor: from establishment of brain death to the
harvesting of the heart.
a Median with range between parentheses.
b p-values are obtained by Mann–Whitney test.
c p-values are obtained by (exact) v2-test.
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primer: 5V-GTC-AGC-TGT-GGT-AAT-CCA-CTT-TCA-T-
3V; HIF-1a probe: FAM-5V-TAG-GAA-TTG-GAA-CAT-
TAT-TAC-AGC-AGC-CAG-ACG-3V; FLIP sense primer:
5V-AGG-CAA-GAT-AAG-CAA-GGA-GAA-GAG-T-3V;
FLIP anti-sense primer: 5V-TTT-TCT-ATT-AAA-TCC-AGT-
TGA-TCT-GGG-3V; FLIP probe: FAM-5V-TCT-TGG-ACC-
TTG-TGG-TTG-AGT-TGG-AGA-AA-3V. PCR conditions
were: incubation at 50 8C for 10 min to enable Uracil
N-glycosylase (present in the mastermix) to destroy
possible amplicons, incubation at 95 8C for 10 min to
activate AmpliTaq Gold polymerase followed by 40 cycles
of 15 sec denaturation at 95 8C and 1 min annealing and
extension at optimal temperatures (59 8C for HO-1, HIF-1a and FLIP(S+L) and 60 8C for TGF-h, Bcl-2, Bax, and
18S). Standard curves with serial dilutions of known
amounts of the target molecules were used to determine
the mRNA concentrations in MB. The measured mRNA
concentrations for the different molecules were stand-
ardized for the 18S concentration.
3.3. Immunohistochemical analysis
Double staining of HO-1 with CD3 (T-cells), CD68
(macrophages) and CD31 (endothelial cells) was performed
on snap frozen MB specimens (n=12, taken at week 1), cut
in 5 Am sections, air-dried and fixed for 10 min in acetone.
The primary antibodies used to stain the samples were
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technology, Santa Cruz, CA) and mouse-anti-human (CD3:
clone SK7, Becton and Dickinson, San Jose, CA; CD68:
clone KP1 and CD31: clone JC/70A Dako, Glostrup,
Denmark). Optimal working dilutions for the antibodies
were previously determined by titration assays. For the
detection of HO-1, we used the ABC method and the PAP
method for CD3, CD68 and CD31. In brief, slides were
rinsed in phosphate-buffered saline (PBS) and incubated
with rabbit-anti-human or mouse anti-human antibodies for
30 min at RT. The slides were then rinsed twice with PBS
and incubated with biotinylated goat-anti-rabbit antibody
(HO-1; Dako) or rabbit-anti-mouse IgG (CD3, CD68 and
CD31; Biogenex, San Ramon CA) for 30 min. The slides
were rinsed with Tris-HCl pH 8 and subsequently labeled
with the ABC complex or PAP complex. The enzyme was
detected with Fast Blue BB Salt (HO-1; Sigma-Aldrich,
Zwijndrecht, The Netherlands) or DAB (CD3, CD68 and
CD31; Sigma) as a substrate, following the manufacturers
instructions. In control sections, the primary antibody was
omitted.
3.4. Statistics
Characteristics of patients with and without TCAD were
compared using the (exact) v2-test for discrete variables and
Mann–Whitney or Student’s t-test for continues variables,
as appropriate. When the exact v2-test was used, the exact
mid p-value was calculated, using StatXact software
(CYTEL Software, Cambridge, MA, USA).
To compare mRNA expression levels between patients
with and without TCAD at the different time points, the
Mann–Whitney test was used. For all tests, pV0.05 was
considered significant.T
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.4. Results
4.1. Patient demographics
The characteristics of recipients with and without
accelerated TCAD were comparable at all time points of
mRNA measurements, except for the number of acute
rejections at time 0 (Table 1). This was higher in the
recipients in which early signs of TCAD were observed at 1
year.
4.2. Intragraft mRNA expression
No differences in mRNA expression levels of any of the
measured parameters were found between patients without
(n=12) and with (n=11) accelerated TCAD in the time 0
biopsies (Table 2, Fig. 1A, HO-1; 1B, TGF-h; 1C, Bcl-2/
Bax). At 1 week, however, higher mRNA expression levels
for HO-1 and TGF-h in biopsies from patients with TCAD
compared to grafts of patients without TCAD were found
Fig. 1. Intragraft mRNA expression at week 1 and month 10 after transplantation of Heme-Oxygenase-1 and TGF-h (A and C) and apoptotic markers FLIP and
Bcl-2/Bax ratio (B and D) in patients with and without transplant coronary artery disease (TCAD). A significant higher mRNA expression for HO-1 and TGF-h
accompanied by a pro-apoptotic shift in the Bcl-2/Bax balance at 1 week after transplantation was found in patients with TCAD. The higher HO-1 and TGF-h
levels were again found at 10 months in TCAD positive patients.
C.T.J. Holweg et al. / Transplant Immunology 13 (2004) 265–272 269(Table 2 and Fig. 1A, HO-1 and 1B, TGF-h). In addition,
we found a lower ratio of the apoptotic markers Bcl-2/Bax
in patients with signs of TCAD (Table 2, Fig. 1C). The
HIF-1a mRNA expression levels were comparable between
the patient groups (Table 2) and also no differences for
FLIP between the two patient groups were measured (Table
2). In biopsies taken at 10 months after transplantation,
again, higher HO-1 and TGF-h mRNA expression levels
were measured in patients with a positive coronary
angiogram (Table 2, Fig. 1A, HO-1 and 1B, TGF-h). In
these samples, no differences in apoptotic markers were
detected between patients with or without TCAD (Table 2,
Fig. 1C, Bcl-2/Bax) and comparable HIF-1a expression
was found (Table 2).
In Fig. 2, we show the HO-1 mRNA expression over
time, with a connecting line between biopsies of one patient.
The consistent cohort of patients was too small for statistical
analysis, but an increased HO-1 mRNA expression was
observed in TCAD positive patients at week 1 thatFig. 2. Intragraft Heme Oxygenase-1 mRNA expression in patients with
and without TCAD over time. The connected dots are biopsies from 1
patient. Week 0: time point at time of transplantation, week 1: 1 week after
transplantation, month 10: 10 months after transplantation.decreased thereafter. We did not observe this in TCAD
negative cardiac recipients.
4.3. Immunohistochemical analysis
Because of subjectivity in quantifying immunohistochem-
ical results, we only used this technique to determine the
origin of the HO-1 production. We studied week 1 biopsies,
because the differences in mRNA expression between
patients with and without TCAD was most striking at this
time point. Only a few CD3 (T-cells) positive cells were
present in the biopsies. These CD3 cells did not express
HO-1. Of the CD31 (endothelial cells) positive cells, a few
cells were positive for HO-1 (b10%). HO-1 expression was
mainly seen in CD68 (macrophages) positive cells (Fig. 3).
All biopsies (n=12) contained CD68 positive cells (range
11-100 cells), which was in accordance with previous
findings [15]. In eight of these biopsies, 50–90% of the
macrophages expressed HO-1. No double staining for HO-1
and cardiomyocytes was performed, but morphological
analysis of the biopsies showed no HO-1 positive cardio-
myocytes.5. Discussion
We investigated HO-1 expression and a possible way by
which HO-1 acts in the initiation and progression of
accelerated TCAD. We measured higher HO-1 and TGF-h
mRNA expression levels in biopsies taken from recipients
with early angiographic signs of TCAD compared to
patients without TCAD at both 1 week and at 10 months
after transplantation. In the week 1 biopsies, these higher
expression levels were accompanied by a shifted Bcl-2/Bax
balance towards the pro-apoptotic marker Bax of the
mitochondrial apoptosis pathway. This indicates that these
patients might be prone to apoptosis and tissue injury due to
apoptosis via this route.
Fig. 3. Immunohistochemical double staining (40) of (A) HO-1 (blue) and
CD3 (T-cells, brown), (B) HO-1 and CD31 (endothelial cells, brown), (C)
HO-1 and CD68 (macrophages, brown) and the negative control (primary
antibody omitted) in myocardial biopsies from TCAD positive patients at 1
week post-transplantation. HO-1 expression is mainly seen in CD68
positive cells.
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who developed TCAD within the first year was unexpected.
In accordance with the findings in rodents, we presumed
that HO-1 would have been higher in TCAD negative heart
transplant recipients [8,9]. Apparently, despite upregulation
of HO-1, accelerated TCAD developed in our patients.
However, also in another human study, in kidney transplant
patients, higher HO-1 mRNA expression was found in
biopsies from patients with acute rejection compared to
patients without. Like in our patients, a higher HO-1 level
seemed not to be protective [7]. Moreover, in the animal
studies, production of HO-1 was induced in the donor organ
before transplantation with CoPP or an adenovirus construct
containing HO-1. In our study, there was no artificialupregulation of HO-1 in the donor heart. In the biopsies of
our heart transplant recipients, HO-1 induction could have
been caused by cellular stress, such as hypoxia, ischemia/
reperfusion and inflammation [16–19]. Hypoxia activates
the transcription factors HIF-1a, NFnB and AP-1 which
subsequently lead to the upregulation of HO-1 [16,20,21].
However, the higher HO-1 expression was not associated
with upregulation of HIF-1a, suggesting that this tran-
scription factor is not the initiator of the HO-1 production in
our patient group. Reperfusion after a period of ischemia
might also lead to upregulation of HO-1. During reperfu-
sion, an oxygen burst occurs, whereby reactive oxygen
species (ROS) are formed [17,22–24]. ROS activate tran-
scription factors, which then can induce expression of pro-
inflammatory cytokines leading to inflammatory responses.
HO-1 is able to suppress inflammatory reactions [19].
Indeed, our immunohistochemical results show that most of
the HO-1 protein is produced by the infiltrating macro-
phages. This suggests that HO-1 is upregulated as an
adaptive response and probably plays a role in the resolution
of the inflammatory responses. Because of the subjectivity
of quantifying immunohistochemical stainings, we did not
determine the correlation between the mRNA expression
levels and the HO-1 protein production by the macrophages.
ROS can also cause tissue damage by inducing mito-
chondrial membrane changes, leading to the release of
apoptogenic factors, which is promoted by Bax and
prevented by Bcl-2 [22–25]. Although, we cannot exclude
that the Bcl-2 and Bax is produced by infiltrating macro-
phages and T-cells, we assume that the balance between
Bcl-2 and Bax might reflect tissue injury due to apoptosis
and the found pro-apoptotic shift in the 1 week biopsies
suggests more tissue damage and, thus, more inflammation
in patients who were going to develop TCAD. In this view,
as mentioned before, the higher HO-1 mRNA expression
might be a response to the injury.
We also confirmed earlier findings of our group that
more TGF-h mRNA is expressed in biopsies from patients
with early signs of TCAD [5]. Since it is known that TGF-h
is involved in wound repair, we assume that TGF-h is
upregulated to repair damaged tissue due to peri-operative
processes. Upregulation of HO-1 by TGF-h might be a
mechanism to govern the repair process [11].
The differential HO-1 expression between patients with
and without TCAD might also be influenced by the
administered immunosuppressive drugs. For example, ste-
roids inhibit activation of NFnB, which is a transcription
factor for HO-1 and, thus, might influence HO-1 expression
[26,27]. However, the patients received similar immuno-
suppressive regimen.
The above considerations only explain the upregulation
of HO-1 as an adaptive inflammatory response to avoid or
limit oxidative damage. However, it does not explain why
there might be more damage in some donor hearts compared
to others. Therefore, we compared donor factors that might
contribute to graft injury, like time of and cause of brain
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This did also not clarify the question, as we could not find a
relation between these parameters and development of
TCAD.
We are aware of the limitations of our study. Our patient
groups are small and the biopsies taken at the different time
points do not reflect a consistent cohort of patients. We
performed a retrospective study in which we selected the
most optimal patient groups with a maximum number of
available biopsies of the chosen time-points. Nevertheless,
consistent data for HO-1, TGF-h and Bcl-2/Bax balance
were generated. Furthermore, visual angiographic assess-
ment of the coronary arteries instead of intravascular
ultrasound (IVUS) was used to define the presence of
abnormalities in the coronary arteries. Visual assessment of
angiograms is less sensitive as only the contrast filled lumen
is assessed. Measurements of vessel wall abnormalities by
IVUS would have been preferable. Unfortunately, such
procedure is not routinely performed at our institution.
Although our preliminary results should be confirmed in a
prospective study with a consistent cohort of patients, we
think that our findings are important, because there is only
limited data of HO-1 expression in human tissue and a
clinical setting available. We conclude that HO-1 expression
is upregulated in grafts with early signs of TCAD compared
to patients who develop TCAD later after transplantation. It
is not clear whether the increase in HO-1 mRNA expression
is the cause or the consequence of TCAD, but our data
suggest that upregulation of HO-1 is an adaptive response to
limit cell and tissue injury and a subsequent inflammation
process. The overexpression of HO-1 might therefore be a
reflection of damage due to the transplantation procedure
and the subsequent inflammatory response.References
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